Target intelligence / Profile preview

UL16-binding protein family (ULBP) (ULBP)

Target
ULBP
Molecular classification
MHC class I-related protein, NKG2D ligand, Glycoprotein
01

Overview

The UL16-binding protein (ULBP) family, also known as the Retinoic Acid Early Transcript 1 (RAET1) family, consists of several MHC class I-related cell surface glycoproteins (ULBP1-6) that function as ligands for the NKG2D activating receptor (Cosman et al., 2001, Immunity). These proteins are generally not expressed on healthy tissues but are highly upregulated under conditions of cellular stress, such as DNA damage, viral infection, or oncogenic transformation (Schmiedel & Mandelboim, 2018, Frontiers in Immunology). This induced-self expression pattern makes them critical markers for immune surveillance, allowing Natural Killer (NK) cells and CD8+ T cells to identify and destroy compromised cells (Spear et al., 2013, Cancer Immunity). In oncology, ULBPs are frequently overexpressed, making them promising targets for various immunotherapeutic approaches, including Chimeric Antigen Receptor (CAR) T-cell therapies like CYAD-01 and bispecific antibodies (Celyad Oncology, 2023). However, many tumors evade this immune recognition by proteolytically shedding ULBPs from the cell surface, creating soluble decoys that block NKG2D receptors and impair effector cell function (Fernández-Messina et al., 2010, Blood). Therapeutic strategies often focus on either targeting the membrane-bound forms or inhibiting the shedding process to restore immune sensitivity.

Other names
RAET1 proteinsRetinoic acid early transcript 1 familyNKG2D ligandsULBP1-6UL16-binding proteins
02

Mechanism of action

Activation of the NKG2D receptor on effector immune cells (NK cells and T cells) to induce targeted lysis of cells expressing ULBP ligands.

03

Biological functions

Immune responseNK cell activationT cell costimulationCellular stress response
04

Disease associations

CancerViral infectionAutoimmune disease
05

Safety considerations

On-target off-tumor toxicity in healthy tissues expressing stress ligandsImmune evasion via ligand sheddingCytokine release syndrome (CRS) associated with CAR-T therapy
06

Interacting drugs

CYAD-01

2 more in the full profile.

07

Biomarkers

ULBP1 surface expressionULBP2 surface expressionSoluble ULBP2 (sULBP2) levelsSoluble ULBP3 (sULBP3) levels

Beyond the preview

Go deeper on UL16-binding protein family (ULBP) (ULBP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on UL16-binding protein family (ULBP) (ULBP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call